Details of the Drug Reposition

General Information of This Drug (ID: DMY78E0)

Drug Name
ADCT-301   DMY78E0
Synonyms camidanlumab tesirine

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
1 Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Hodgkin lymphoma DISX2OUL 2B30 Phase 2 [1]
------------------------------------------------------------------------------------
3 Phase 1 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Acute myeloid leukaemia DIS0BM1I 2A60 Phase 1 [2]
Lymphoma DISN6V4S 2A80-2A86 Phase 1 [3]
Acute lymphoblastic leukaemia DIS87TGM 2A85 Phase 1 [2]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT04052997) Study to Evaluate the Efficacy and Safety of Camidanlumab Tesirine (ADCT-301) in Patients With Relapsed or Refractory Hodgkin Lymphoma. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)